TD Asset Management Inc Purchases 3,765 Shares of Insulet Corporation $PODD

TD Asset Management Inc lifted its stake in shares of Insulet Corporation (NASDAQ:PODD) by 15.1% in the second quarter, HoldingsChannel reports. The fund owned 28,753 shares of the medical instruments supplier’s stock after acquiring an additional 3,765 shares during the period. TD Asset Management Inc’s holdings in Insulet were worth $9,034,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in PODD. American Century Companies Inc. grew its stake in shares of Insulet by 34.8% during the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock valued at $302,686,000 after acquiring an additional 297,734 shares during the period. Nuveen LLC bought a new position in shares of Insulet during the 1st quarter valued at approximately $74,163,000. Kayne Anderson Rudnick Investment Management LLC grew its stake in shares of Insulet by 1,316.5% during the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 193,511 shares of the medical instruments supplier’s stock valued at $50,818,000 after acquiring an additional 179,850 shares during the period. Vanguard Group Inc. grew its stake in shares of Insulet by 2.1% during the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock valued at $2,276,553,000 after acquiring an additional 178,976 shares during the period. Finally, Federated Hermes Inc. grew its stake in shares of Insulet by 23.4% during the 1st quarter. Federated Hermes Inc. now owns 632,869 shares of the medical instruments supplier’s stock valued at $166,198,000 after acquiring an additional 120,197 shares during the period.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on PODD shares. Zacks Research upgraded Insulet from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 14th. Barclays boosted their price objective on Insulet from $266.00 to $300.00 and gave the company an “equal weight” rating in a research note on Thursday, August 21st. Wells Fargo & Company boosted their price target on Insulet from $330.00 to $350.00 and gave the stock an “overweight” rating in a report on Friday, August 8th. Leerink Partners boosted their price target on Insulet from $339.00 to $355.00 and gave the stock an “outperform” rating in a report on Tuesday, October 14th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Insulet in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $348.05.

Insider Activity at Insulet

In other news, SVP Prem Singh sold 687 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This represents a 16.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by corporate insiders.

Insulet Stock Up 0.7%

NASDAQ PODD opened at $318.59 on Monday. The stock’s 50 day moving average is $326.22 and its 200 day moving average is $302.53. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. Insulet Corporation has a 12 month low of $226.50 and a 12 month high of $353.50. The stock has a market cap of $22.43 billion, a PE ratio of 96.84, a P/E/G ratio of 2.66 and a beta of 1.40.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.25. The business had revenue of $649.10 million for the quarter, compared to analysts’ expectations of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company’s revenue for the quarter was up 32.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Research analysts predict that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.